BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 25117294)

  • 21. Somatic mutations in
    Gao LM; Zhao S; Zhang WY; Wang M; Li HF; Lizaso A; Liu WP
    Cancer Biol Ther; 2019; 20(10):1319-1327. PubMed ID: 31311407
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model.
    Ito A; Ishida T; Yano H; Inagaki A; Suzuki S; Sato F; Takino H; Mori F; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
    Cancer Immunol Immunother; 2009 Aug; 58(8):1195-206. PubMed ID: 19048251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Application of flow cytometric in situ hybridization assay to Epstein-Barr virus-associated T/natural killer cell lymphoproliferative diseases.
    Kawabe S; Ito Y; Gotoh K; Kojima S; Matsumoto K; Kinoshita T; Iwata S; Nishiyama Y; Kimura H
    Cancer Sci; 2012 Aug; 103(8):1481-8. PubMed ID: 22497716
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Application of Anti-CCR4 Monoclonal Antibody.
    Ueda R
    Oncology; 2015; 89 Suppl 1():16-21. PubMed ID: 26550987
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rapid identification and characterization of infected cells in blood during chronic active Epstein-Barr virus infection.
    Fournier B; Boutboul D; Bruneau J; Miot C; Boulanger C; Malphettes M; Pellier I; Dunogué B; Terrier B; Suarez F; Blanche S; Castelle M; Winter S; Delecluse HJ; Molina T; Picard C; Ehl S; Moshous D; Galicier L; Barlogis V; Fischer A; Neven B; Latour S
    J Exp Med; 2020 Nov; 217(11):. PubMed ID: 32812031
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disorders.
    Park S; Ko YH
    J Dermatol; 2014 Jan; 41(1):29-39. PubMed ID: 24438142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epstein-Barr virus reactivation is induced, but abortive, in cutaneous lesions of systemic hydroa vacciniforme and hypersensitivity to mosquito bites.
    Yamamoto T; Hirai Y; Miyake T; Hamada T; Yamasaki O; Morizane S; Fujimoto W; Iwatsuki K
    J Dermatol Sci; 2016 Jun; 82(3):153-9. PubMed ID: 27039668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transcriptional profiling of Epstein-Barr virus (EBV) genes and host cellular genes in nasal NK/T-cell lymphoma and chronic active EBV infection.
    Zhang Y; Ohyashiki JH; Takaku T; Shimizu N; Ohyashiki K
    Br J Cancer; 2006 Feb; 94(4):599-608. PubMed ID: 16449999
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unrelated bone marrow transplantation for Epstein-Barr virus-associated T/NK-cell lymphoproliferative disease.
    Okamura T; Kishimoto T; Inoue M; Honda M; Yamashita N; Wakiguchi H; Yagita M; Hosoi G; Sako M; Yasui M; Yagi K; Kawa K
    Bone Marrow Transplant; 2003 Jan; 31(2):105-11. PubMed ID: 12621491
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorders.
    Cai Q; Chen K; Young KH
    Exp Mol Med; 2015 Jan; 47(1):e133. PubMed ID: 25613730
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epstein - Barr virus positive T and NK-cell lymphoproliferations: Morphological features and differential diagnosis.
    Montes-Mojarro IA; Kim WY; Fend F; Quintanilla-Martinez L
    Semin Diagn Pathol; 2020 Jan; 37(1):32-46. PubMed ID: 31889602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Common cytological and cytogenetic features of Epstein-Barr virus (EBV)-positive natural killer (NK) cells and cell lines derived from patients with nasal T/NK-cell lymphomas, chronic active EBV infection and hydroa vacciniforme-like eruptions.
    Zhang Y; Nagata H; Ikeuchi T; Mukai H; Oyoshi MK; Demachi A; Morio T; Wakiguchi H; Kimura N; Shimizu N; Yamamoto K
    Br J Haematol; 2003 Jun; 121(5):805-14. PubMed ID: 12780797
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas.
    Remer M; Al-Shamkhani A; Glennie M; Johnson P
    Immunotherapy; 2014; 6(11):1187-206. PubMed ID: 25496334
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinicopathologic features of systemic EBV-positive T/NK-cell lymphoproliferative disease in adults].
    Zheng XD; Zhou XG; Jin Y; Xie JL; Wei XJ; Chen SY; Mei X; Gong LP; Lü BB
    Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):227-34. PubMed ID: 21615995
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinicopathological findings, prognosis, and Epstein-Barr virus infection in rheumatoid arthritis patients with other iatrogenic immunodeficiency-associated T- and NK-cell lymphoproliferative disorders.
    Kimura S; Oshiro Y; Iwasaki H; Kadowaki M; Ogata M; Daa T; Sakata T; Kawauchi S; Wang Z; Takamatsu Y; Takeshita M
    BMC Cancer; 2022 Dec; 22(1):1342. PubMed ID: 36544095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathogenic link between hydroa vacciniforme and Epstein-Barr virus-associated hematologic disorders.
    Iwatsuki K; Satoh M; Yamamoto T; Oono T; Morizane S; Ohtsuka M; Xu ZG; Suzuki D; Tsuji K
    Arch Dermatol; 2006 May; 142(5):587-95. PubMed ID: 16702496
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia-lymphoma: cutaneous adverse reactions may predict the prognosis.
    Yonekura K; Kanzaki T; Gunshin K; Kawakami N; Takatsuka Y; Nakano N; Tokunaga M; Kubota A; Takeuchi S; Kanekura T; Utsunomiya A
    J Dermatol; 2014 Mar; 41(3):239-44. PubMed ID: 24628073
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disease in Japan.
    Sato E; Ohga S; Kuroda H; Yoshiba F; Nishimura M; Nagasawa M; Inoue M; Kawa K
    Am J Hematol; 2008 Sep; 83(9):721-7. PubMed ID: 18626884
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of skin blister fluids from children with Epstein-Barr virus-associated lymphoproliferative disease.
    Wada T; Toma T; Miyazawa H; Koizumi E; Shirahashi T; Matsuda Y; Yachie A
    J Dermatol; 2018 Apr; 45(4):444-449. PubMed ID: 29352500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic and disease severity determination criteria for hydroa vacciniforme lymphoproliferative disorders and severe mosquito bite allergy.
    Hirai Y; Asada H; Hamada T; Kawada JI; Kimura H; Arai A; Ohshima K; Ohga S; Iwatsuki K;
    J Dermatol; 2023 Jul; 50(7):e198-e205. PubMed ID: 37249004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.